W. Wiest

500 total citations
20 papers, 289 citations indexed

About

W. Wiest is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, W. Wiest has authored 20 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in W. Wiest's work include Cancer Treatment and Pharmacology (7 papers), Advanced Breast Cancer Therapies (4 papers) and HER2/EGFR in Cancer Research (4 papers). W. Wiest is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Advanced Breast Cancer Therapies (4 papers) and HER2/EGFR in Cancer Research (4 papers). W. Wiest collaborates with scholars based in Germany, Italy and Netherlands. W. Wiest's co-authors include Roland Moll, Ingrid Moll, R. Ruffmann, H. Weidinger, Gϋnter von Minckwitz, Iris Schrader, Sibylle Loibl, Enrico Colli, Serban Dan Costa and Anke Kleine-Tebbe and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Cancer.

In The Last Decade

W. Wiest

19 papers receiving 271 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. Wiest Germany 6 175 81 69 61 54 20 289
B Lane Netherlands 6 154 0.9× 104 1.3× 59 0.9× 75 1.2× 72 1.3× 8 343
Balvinder K. Bloor United Kingdom 10 134 0.8× 173 2.1× 35 0.5× 58 1.0× 73 1.4× 15 421
Els Groeneveld Netherlands 7 146 0.8× 155 1.9× 27 0.4× 57 0.9× 137 2.5× 12 405
Karen A. Holbrook United States 9 164 0.9× 99 1.2× 66 1.0× 82 1.3× 12 0.2× 11 342
Vesarat Wessagowit United Kingdom 15 230 1.3× 191 2.4× 176 2.6× 102 1.7× 59 1.1× 31 660
N. Murase Japan 13 97 0.6× 129 1.6× 11 0.2× 34 0.6× 60 1.1× 28 344
Z. Gao United States 9 117 0.7× 189 2.3× 89 1.3× 26 0.4× 18 0.3× 11 409
Hiroki Fujikawa Japan 11 90 0.5× 167 2.1× 95 1.4× 85 1.4× 31 0.6× 29 399
Christoph M. Lanschuetzer Austria 12 189 1.1× 110 1.4× 31 0.4× 57 0.9× 56 1.0× 18 378
K. Katsuoka Japan 12 79 0.5× 32 0.4× 120 1.7× 162 2.7× 14 0.3× 37 353

Countries citing papers authored by W. Wiest

Since Specialization
Citations

This map shows the geographic impact of W. Wiest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Wiest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Wiest more than expected).

Fields of papers citing papers by W. Wiest

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Wiest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Wiest. The network helps show where W. Wiest may publish in the future.

Co-authorship network of co-authors of W. Wiest

This figure shows the co-authorship network connecting the top 25 collaborators of W. Wiest. A scholar is included among the top collaborators of W. Wiest based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Wiest. W. Wiest is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thomssen, Christoph, Martina Vetter, Eva Johanna Kantelhardt, et al.. (2023). Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group. Cancers. 15(5). 1580–1580.
2.
3.
Loibl, Sibylle, Gabriele Doering, Lothar Müller, et al.. (2011). Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial. Breast Care. 6(6). 457–461. 1 indexed citations
4.
Kaufmann, M., Nicolaì Maass, Serban Dan Costa, et al.. (2010). First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial. European Journal of Cancer. 46(18). 3184–3191. 30 indexed citations
5.
Janni, W, et al.. (2010). A phase II randomized trial of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC).. Journal of Clinical Oncology. 28(15_suppl). TPS135–TPS135. 2 indexed citations
6.
Kaufmann, M., Marc Sütterlin, Iris Schrader, et al.. (2009). 5002 MoniCa: A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer (GBG39). European Journal of Cancer Supplements. 7(2). 260–260. 4 indexed citations
7.
Klaassen, U., T. Bauknecht, H. Kühnle, et al.. (1995). 492 Safety and efficacy of taxol® (paclitaxel) over 3h in 306 platinum-refractory patients with ovarian cancer: Results of a German cooperative study. European Journal of Cancer. 31. S105–S105. 2 indexed citations
8.
Wiest, W., et al.. (1989). Comparison of Single Administration with an Ovule of 600 mg Fenticonazole versus a 500 mg Clotrimazole Vaginal Pessary in the Treatment of Vaginal Candidiasis. Journal of International Medical Research. 17(4). 369–372. 9 indexed citations
9.
Wiest, W. & R. Ruffmann. (1987). Short-term Treatment of Vaginal Candidiasis with Fenticonazole Ovules: a Three-dose Schedule Comparative Trial. Journal of International Medical Research. 15(5). 319–325. 10 indexed citations
10.
Wiest, W., et al.. (1986). Serum ribonuclease activity in patients with ovarian tumors.. PubMed. 7(2). 76–81. 1 indexed citations
11.
Spelsberg, F., et al.. (1985). Biliary Concentrations of Temocillin. Drugs. 29(Supplement 5). 122–127. 2 indexed citations
12.
Wiest, W., et al.. (1984). Determination of ribonuclease activity in the serum of ovarian carcinoma patients.. PubMed. 5(3). 186–93. 1 indexed citations
13.
Wiest, W., et al.. (1984). Peridurale Morphin-Analgesie zur Bekämpfung von tumorbedingten Schmerzen bei gynäkologischen Karzinompatientinnen. Geburtshilfe und Frauenheilkunde. 44(8). 503–505. 1 indexed citations
14.
Moll, Roland, Ingrid Moll, & W. Wiest. (1982). Changes in the Pattern of Cytokeratin Polypeptides in Epidermis and Hair Follicles During Skin Development in Human Fetuses. Differentiation. 23(1-3). 170–178. 203 indexed citations
15.
Wiest, W., et al.. (1980). Increasing human serum ribonuclease activity is a concomitant phenomenon of ovarian carcinoma. Journal of Cancer Research and Clinical Oncology. 97(3). 307–314. 5 indexed citations
16.
Wiest, W., et al.. (1980). [Serum ribonuclease activity in gynecologic neoplasms. The behavior of serum ribonuclease in ovarian cancer under cytostatic therapy].. PubMed. 98(36). 1384–6. 1 indexed citations
17.
Wiest, W., et al.. (1979). [Serum ribonuclease activity in patients with gynaecologic malignomas (author's transl)].. PubMed. 39(11). 940–6. 1 indexed citations
18.
Kachel, W., et al.. (1979). [Changes in blood coagulation during tocolysis].. PubMed. 228(1-4). 633–4. 1 indexed citations
19.
Wiest, W., et al.. (1979). [Partusisten and isoptin influence on maternal ECG and heart-specific serum enzymes].. PubMed. 228(1-4). 134–5. 1 indexed citations
20.
Weidinger, H. & W. Wiest. (1974). A comparative study of the epidemiological data of pregnancies with and without tendencies to prematute delivery. Journal of Perinatal Medicine. 2(4). 276–287. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B Lane Breakdown of academic impact, for papers by Balvinder K. Bloor Breakdown of academic impact, for papers by Els Groeneveld Breakdown of academic impact, for papers by Karen A. Holbrook Breakdown of academic impact, for papers by Vesarat Wessagowit Breakdown of academic impact, for papers by N. Murase Breakdown of academic impact, for papers by Z. Gao Breakdown of academic impact, for papers by Hiroki Fujikawa Breakdown of academic impact, for papers by Christoph M. Lanschuetzer Breakdown of academic impact, for papers by K. Katsuoka
Rankless by CCL
2026